<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRETTEN- coagulation factor xiii a-subunit (recombinant) 
			 </strong><br>Novo Nordisk<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TRETTEN safely and effectively. See full prescribing information for TRETTEN.  <br>TRETTEN, Coagulation Factor XIII A-Subunit (Recombinant) <br>For Intravenous Use. Lyophilized Powder for Solution for Injection<br>Initial U.S. Approval: 2013</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">TRETTEN, Coagulation Factor XIII A-Subunit (Recombinant), is indicated for routine prophylaxis of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with congenital factor XIII A-subunit deficiency. (<a href="#i4i_indications_id_bbe93fe0-968c-4d5a-8975-5e31a8455eb9">1</a>) </p>
<p class="Highlighta">TRETTEN is not for use in patients with congenital factor XIII B‑subunit deficiency. (<a href="#i4i_indications_id_bbe93fe0-968c-4d5a-8975-5e31a8455eb9">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For intravenous use only.</span> </p>
<p class="Highlighta">Dose: </p>
<dl>
<dt>•</dt>
<dd>35 international units per kilogram body weight once monthly to achieve a target trough level of  FXIII activity at or above 10% using a validated assay. (<a href="#i4i_section_id_f02659bf-5255-45c9-8e87-d7f63b95bd68">2.1</a>)</dd>
<dt>•</dt>
<dd>Consider dose adjustment if adequate coverage is not achieved with a 35 IU/kg dose. (<a href="#i4i_section_id_f02659bf-5255-45c9-8e87-d7f63b95bd68">2.1</a>)</dd>
<dt>•</dt>
<dd>Once reconstituted, TRETTEN may be diluted with 0.9% sodium chloride to facilitate measurement of small volumes. <a href="#ID_2ab9ac32-2790-477e-a46a-4e2d4b59d460">(2.2)</a>
</dd>
</dl>
<p class="Highlighta">Rate: Do not exceed 1-2 mL per minute. (<a href="#i4i_section_id_42514a8f-c4fc-4d70-9402-a33506a7782f">2.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Lyophilized powder in single-use vial containing 2000 - 3125 IU of recombinant coagulation factor XIII A-subunit.</dd>
<dt>•</dt>
<dd>After reconstitution with 3.2 mL of sterile water for injection, each vial contains 667-1042 IU/mL of recombinant coagulation factor XIII A-subunit. </dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the active substance or to any of the excipients.  (<a href="#i4i_contraindications_id_dd745ac2-0d80-4060-a196-d542dc4a263c">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Discontinue if allergic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur. (<a href="#i4i_section_id_f0844e7a-bf79-48bf-b14f-add773e4bc99">5.1</a>)</dd>
<dt>•</dt>
<dd>Monitor patients for <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. (<a href="#i4i_section_id_8fae96f1-d8bd-4d8f-a499-b9e166a6ff66">5.2</a>)</dd>
<dt>•</dt>
<dd>Analyze for neutralizing antibodies if FXIII activity fails to reach expected levels or if reduced therapeutic effect is observed. (<a href="#i4i_section_id_4155c607-5f60-4535-b08b-1bb6d3c0550b">5.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions reported in the clinical trials (≥1%) were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the extremities, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, D dimer increase. <a href="#i4i_adverse_effects_id_11bbbbd7-3b6f-4374-b654-8f3c8101db1b">(6)</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-844-873-8836 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt> </dt>
<dd>Do not administer TRETTEN with recombinant factor VIIa. (<a href="#i4i_interactions_id_3417b164-e2a8-45f5-9f8f-536639a59ef4">7</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt> </dt>
<dd>Pregnancy: No human or animal data available.  Use only if clearly needed. <a href="#i4i_pregnancy_id_6c71b957-d690-4f8e-a811-1541b7e08068">(8.1)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dose </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Reconstitution</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Thromboembolic Risk</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Inhibitors</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_bbe93fe0-968c-4d5a-8975-5e31a8455eb9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">TRETTEN, Coagulation Factor XIII A-Subunit (Recombinant), is indicated for routine prophylaxis for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with congenital factor XIII A-subunit deficiency. </p>
<p>TRETTEN is not for use in patients with congenital factor XIII B‑subunit deficiency</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c5b31dbb-cb4c-48c6-a3d6-6c2b56ebcfcf"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravenous use only.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f02659bf-5255-45c9-8e87-d7f63b95bd68"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dose </h2>
<dl>
<dt>•</dt>
<dd>Treatment should be initiated under the supervision of a physician experienced in the treatment of rare <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders.</dd>
<dt>•</dt>
<dd>The dose for routine prophylaxis for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with congenital factor XIII (FXIII) A-subunit deficiency is 35 international units (IU) per kilogram body weight once monthly to achieve a target trough level of FXIII activity at or above 10% using a validated assay.</dd>
<dt>•</dt>
<dd>Consider dose adjustment if adequate coverage is not achieved with the recommended 35 IU/kg dose.<p class="First">A pharmacokinetic study was conducted in the FXIII congenitally deficient population evaluating five dose cohorts (2, 7, 24, 60 and 89 IU/kg) with blood sampling at 0.5, 1, 4, 8, 24, 48, 72 hours, and 7, 14, and 28 days. Samples were tested for FXIII activity by a chromogenic assay and for FXIII A<span class="Sub">2</span>B<span class="Sub">2 </span>tetramer levels by an ELISA, as well as for other analytes. It was found that FXIII tetramer levels were proportional to the observed FXIII activity up to the point of replacement of 100% of normal FXIII activity, but there was  no increase in FXIII tetramer levels at higher levels of FXIII activity. A dose of 35 IU/kg is sufficient to replace 100% of FXIII activity in this population, and higher doses may not increase the levels of tetrameric Factor XIII. </p>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2ab9ac32-2790-477e-a46a-4e2d4b59d460"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Reconstitution</h2>
<p class="First">Reconstitute only with sterile water for injection (provided with TRETTEN). The product can be reconstituted using the vial adapter included or a needle.</p>
<div class="Figure">
<a name="id511497597"></a><img alt="Tretten Vials" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-01.jpg">
</div>
<div class="Figure">
<a name="id1952509338"></a><img alt="Vial Adapter" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-02.jpg">
</div>
<p>Reconstitute using the following procedures:</p>
<dl>
<dt> </dt>
<dd>1. Use aseptic technique.</dd>
<dt> </dt>
<dd>2. Wash hands before starting. </dd>
<dt> </dt>
<dd>3. Bring TRETTEN (white lyophilized powder) and sterile water for injection (diluent) to room temperature, but not above 25°C (77°F).</dd>
<dt> </dt>
<dd>4. Remove the plastic caps from the two vials.</dd>
<dt> </dt>
<dd>5. Clean the rubber stoppers on the vials with sterile alcohol swabs and allow them to dry before use.</dd>
<dt> </dt>
<dd>6. Remove the protective paper from the vial adapter, but do not unscrew the protective cap. Attach the vial adapter to the diluent vial, without taking the vial adapter out of the protective cap. Once attached, remove the protective cap from the vial adapter by lightly squeezing the protective cap with your thumb and index finger as shown on the figure below.</dd>
</dl>
<div class="Figure">
<a name="id-1903054816"></a><img alt="Remove protective paper from the vial adapter" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-03.jpg">
</div>
<div class="Figure">
<a name="id598151984"></a><img alt="Remove the tab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-04.jpg">
</div>
<dl>
<dt> </dt>
<dd>7. Draw back the plunger of the sterile syringe and admit a volume of 3.2 mL air into the syringe.</dd>
</dl>
<div class="Figure">
<a name="id1714150246"></a><img alt="Draw back the plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-05.jpg">
</div>
<dl>
<dt> </dt>
<dd>8. Screw the syringe onto the vial adapter on the diluent vial.</dd>
</dl>
<div class="Figure">
<a name="id1032300626"></a><img alt="Screw the syringe onto the adapter" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-06.jpg">
</div>
<dl>
<dt> </dt>
<dd>9. Inject the air from the syringe into the diluent vial until resistance is felt. Then hold the syringe with the diluent vial upside down and withdraw 3.2 mL water into the syringe.</dd>
</dl>
<div class="Figure">
<a name="id-1247568122"></a><img alt="Inject air from the syringe" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-07.jpg">
</div>
<dl>
<dt> </dt>
<dd>10. Remove the empty diluent vial by tipping the syringe with the attached vial adapter.</dd>
</dl>
<div class="Figure">
<a name="id-96403367"></a><img alt="Remove the empty diluent vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-08.jpg">
</div>
<dl>
<dt> </dt>
<dd>11. Attach the syringe with the vial adapter to the powder vial. Hold the syringe slightly tilted with vial facing downwards. Push the plunger slowly to inject all water (3.2 mL) into the powder vial. <span class="Bold">Do not inject the diluent directly on the TRETTEN powder to avoid foaming.</span>
</dd>
</dl>
<div class="Figure">
<a name="id-1720038648"></a><img alt="Attach the syringe to the powder vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-09.jpg">
</div>
<dl>
<dt> </dt>
<dd>12. Gently swirl the vial until all material is dissolved<span class="Bold">. Do not shake the vial</span>. The reconstituted TRETTEN is a clear and colorless solution. Use the reconstituted TRETTEN immediately. If not, store the solution refrigerated or at room temperature not to exceed 25°C (77°F) for up to three hours. Discard after three hours.</dd>
</dl>
<div class="Figure">
<a name="id1185028553"></a><img alt="Gently swirl the vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-10.jpg">
</div>
<dl>
<dt> </dt>
<dd><span class="Underline">NOTE:</span></dd>
</dl>
<dl>
<dt>•</dt>
<dd>For larger dose that requires multiple vials of TRETTEN, reconstitute each additional vial using the same procedure with a separate syringe. </dd>
<dt>•</dt>
<dd>For smaller dose that requires less than the full volume in the vial, reconstituted TRETTEN may be diluted with 0.9% sodium chloride to facilitate measurement of small volumes. Discard remaining product.</dd>
<dt>•</dt>
<dd>For home administration, any such changes should be communicated by the pharmacist or healthcare provider to the patient or family.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42514a8f-c4fc-4d70-9402-a33506a7782f"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<dl>
<dt>•</dt>
<dd>Inspect the reconstituted TRETTEN visually for particulate matter and discoloration prior to administration. Do not use if particulate matter or discoloration is observed.</dd>
<dt>•</dt>
<dd>Administer at a rate not exceeding 1-2 mL per minute.</dd>
<dt>•</dt>
<dd>Do not administer with other infusion solutions.</dd>
<dt>•</dt>
<dd>Do not administer as drip.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_b27efdb3-8243-4e66-98b0-14780761e472"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TRETTEN, Coagulation Factor XIII A-Subunit (Recombinant), is available as a white lyophilized powder in single-use vial containing nominally 2500 IU per vial (2000 – 3125 IU) of recombinant coagulation factor XIII A-subunit. The actual amount of TRETTEN in IU is stated on each carton and vial. </p>
<p>After reconstitution with the provided Sterile Water for Injection, each vial contains 667-1042 IU/mL recombinant coagulation factor XIII A-subunit. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_dd745ac2-0d80-4060-a196-d542dc4a263c"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">TRETTEN is contraindicated in patients who have known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the active substance or to any of the excipients <span class="Italics">[<a href="#i4i_description_id_bd2f42ef-f9e6-4062-aaf8-a0679369a6cc">See Description (11</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_f69083b5-95ff-4e92-922e-de896accc5b5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f0844e7a-bf79-48bf-b14f-add773e4bc99"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">TRETTEN may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.  If signs or symptoms of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) occur, discontinue immediately and institute appropriate treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8fae96f1-d8bd-4d8f-a499-b9e166a6ff66"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Thromboembolic Risk</h2>
<p class="First">Thromboembolic complications may occur.  Monitor patients with conditions that predispose to <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> after administration of TRETTEN. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4155c607-5f60-4535-b08b-1bb6d3c0550b"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Inhibitors</h2>
<p class="First">Inhibitory antibodies may occur with TRETTEN. Patients with inhibitory antibodies may manifest as an inadequate response to treatment. If expected plasma FXIII activity levels are not attained, or if breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_11bbbbd7-3b6f-4374-b654-8f3c8101db1b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reactions reported in clinical trials (≥1%), were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the extremities, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, and increase in fibrin D dimer levels.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_abb1b092-b9f7-47be-8c87-38889a8f54b3"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>During clinical development, TRETTEN was administered to 77 patients with congenital factor XIII A-subunit deficiency (3:2, male: female ratio) for a total of 1990 doses.  Fifty patients (65%) were between the ages of 18 and 77 years (received 1338 doses), 21 patients (27%) were between the ages of 6 and less than 18 years old (received 560 doses), and 6 patients (8%) were less than 6 years old (received 92 doses). Patients were exposed for up to 4.5 years.</p>
<p>Of the 77 patients, 68 received 1979 monthly doses of 35 IU/kg of TRETTEN for routine prophylaxis of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Eleven single doses of TRETTEN have been administered to nine patients for pharmacokinetic investigations.</p>
<p>The adverse drug reactions reported included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the extremities, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the injection site, and increase in fibrin D dimer levels (without evidence of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>). </p>
<p><span class="Italics">Immunogenicity</span></p>
<p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to TRETTEN with the incidence of antibodies to other products may be misleading.</p>
<p>Low level, non-neutralizing antibodies were seen in four of the 77 patients with congenital FXIII A-subunit deficiency. They were all under the age of 18 years. Three of these patients discontinued from trial after development of antibodies. All four<span class="Italics"> </span>patients received at least two<span class="Italics"> </span>doses, with at least one dose given subsequent to the formation of the non-neutralizing antibodies. These antibodies were not found to be of clinical significance. </p>
<p>In another  study including 50 healthy subjects (29 males, 21 females), who were given 2 doses of TRETTEN, one subject developed low-titer, transient non-neutralizing antibodies after receiving the first dose of TRETTEN. The antibodies had no inhibitory activity, and the antibodies disappeared in the 6-month follow up.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_3417b164-e2a8-45f5-9f8f-536639a59ef4"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> may occur if TRETTEN is administered concomitantly with factor VIIa <span class="Italics">[<a href="#i4i_animal_pharmacology_id_6526500e-6fde-4cdc-b595-fb9eaa6482d7">See Nonclinical Pharmacology (13.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_b7211c58-b3b0-4b02-9a99-854e34db9ef7"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6c71b957-d690-4f8e-a811-1541b7e08068"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with TRETTEN. It is also not known whether TRETTEN can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TRETTEN should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e5e76537-4334-4db9-810d-7fe5d1683c82"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether TRETTEN is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRETTEN is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1a371d2c-d1ec-4826-8cda-4ba77bef5afc"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Pediatric patients in the phase 3 study and the extension study included 6 children in the age range 0-5, 12 children in the age range 6-12, and 9 adolescents in the age range 13-17 who were treated with TRETTEN for a total of 652 exposures. Adverse reactions were more frequently reported in patients aged from 6 to less than 18 years old than in adults; a greater number of possible/probably trial drug related events were reported in the patients below 18 years of age (6 patients with 11 events in 27 enrolled patients) than in those above 18 years (3 patients with 3 events in 41 enrolled patients). Three patients under 18 years experienced non-neutralizing antibodies and were withdrawn from the study.  A fourth pediatric patient who had a non-neutralizing antibody remained in the trial. No dose adjustment is required for pediatric age group. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_db4a4098-ac77-412b-9288-abda474f70b9"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The safety and efficacy of TRETTEN in the geriatric population have not been established due to an insufficient number of patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a4ada62e-8961-4c09-95da-50e1160e21f1"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">One patient accidentally received a dose 2.3 times the recommended dose. No clinical signs and symptoms were observed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_bd2f42ef-f9e6-4062-aaf8-a0679369a6cc"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">TRETTEN, Coagulation Factor XIII A-Subunit (Recombinant), is a recombinant human factor XIII-A<span class="Sub">2</span> homodimer composed of two factor XIII (FXIII) A-subunits. The FXIII A-subunit is a 731 amino acid chain with an acetylated N-terminal serine. When FXIII is activated by thrombin, a 37 amino acid peptide is cleaved from the N-terminus of the A‑subunit. </p>
<p>TRETTEN is manufactured as an intracellular, soluble protein in yeast (Saccharomyces cerevisiae) production <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> containing the episomal expression vector, pD16. It is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography.  No human or animal derived products are used in the manufacturing process.</p>
<p>TRETTEN is supplied as a sterile, white lyophilized powder in a single use vial. Table 1 and Table 2 list the vial content of reconstituted TRETTEN and the diluent, respectively.</p>
<a name="_Refid_5002368c-703b-4347-b716-4616b04d3"></a><table>
<caption><span>Table 1 Content of Reconstituted TRETTEN*</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Content</span></p></td>
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Per Vial</span>*</p></td>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Function</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Coagulation Factor XIII A-Subunit (Recombinant)</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">2000 - 3125 IU </p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Active substance</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Sodium Chloride</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">8.70 mg</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Stabilizer</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Sucrose</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">174.0 mg</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Stabilizer</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Polysorbate 20</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">0.30 mg</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Surfactant</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First">L-Histidine</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">9.30 mg</p></td>
<td class="Botrule" valign="top"><p class="First">Buffer</p></td>
</tr>
</tbody>
</table>
<p> *Values are given per 3 mL reconstituted TRETTEN.</p>
<a name="_Refid_1e74b51c-f88b-4cc1-a9bd-fd4ea50bf"></a><table>
<caption><span>Table 2 Content of Diluent for Reconstitution of TRETTEN</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">Content</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Per Vial</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Function</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Sterile Water for Injection</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">3.2 mL</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">Diluent</p></td>
</tr>
</tbody>
</table>
<p>After reconstitution with 3.2 mL sterile water for injection, each vial contains 667-1042 IU/mL of recombinant coagulation factor XIII A-subunit. The reconstituted solution has a pH of approximately 8.0. The formulation contains no preservative and must only be administered intravenously.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_84d4cec3-84e8-4bf2-812d-c467097ea6a2"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_bb3cdd4e-a588-404b-8f41-383cc7430e36"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">FXIII is the terminal enzyme in the blood coagulation cascade. When activated by thrombin at the site of vessel wall injury, FXIII plays an important role in the maintenance of hemostasis through cross-linking of fibrin and other proteins in the fibrin clot. </p>
<p>In plasma, FXIII circulates as a heterotetramer [A<span class="Sub">2</span>B<span class="Sub">2</span>] composed of two FXIII A-subunits and two FXIII B-subunits held together by strong non-covalent interactions. The FXIII A is the catalytic subunit and FXIII B-subunit acts as carrier molecule for the FXIII A-subunit in circulation, and is present in excess in plasma. When FXIII A-subunit is bound to FXIII B-subunit [A<span class="Sub">2</span>B<span class="Sub">2</span>] the half-life of the FXIII A-subunit [A<span class="Sub">2</span>] is prolonged. FXIII is a pro-enzyme (protransglutaminase), which is activated by thrombin in the presence of Ca<span class="Sup">2+</span>. The enzymatic activity resides with the FXIII A-subunit. Upon activation, the FXIII A‑subunit dissociates from the FXIII B-subunit and thereby exposes the active site of the FXIII A-subunit. The active transglutaminase cross-links fibrin and other proteins resulting in increased mechanical strength and resistance to <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span> of the fibrin clot and contributes to enhance platelet and clot <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> to injured tissue.</p>
<p>Coagulation Factor XIII A-Subunit (Recombinant) is a protransglutaminase (rFXIII [rA<span class="Sub">2</span>] homodimer) and binds to free human FXIII B-subunit resulting in a heterotetramer [rA<span class="Sub">2</span>B<span class="Sub">2</span>] with a similar half-life to [A<span class="Sub">2</span>B<span class="Sub">2</span>]. rFXIII has been shown to be activated by thrombin in the presence of Ca<span class="Sup">2+</span>. Activated rFXIII has been shown in dose-dependent manner to increase mechanical strength of fibrin clots, retard <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>, and rFXIII has been shown to enhance platelet <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> to the site of injury. After combining with available plasma B-subunits, Coagulation Factor XIII A-subunit (Recombinant) has been shown to have the same pharmacodynamic properties in plasma as endogenous FXIII.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_9d20fbc7-cd0f-4981-a20f-cc5399947401"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">A qualitative assay of clot solubility is widely used as an indicator of FXIII deficiency; when performed correctly the test is positive only when the FXIII activity in the sample is close to zero.  The results of standard coagulation tests are normal as it is the quality of the clot that is affected.  In addition, at present there are no markers that can quantitatively assess the <span class="Italics">in vivo </span>pharmacodynamics of FXIII.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a69ba553-605d-4105-9778-84f76275204f"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Steady State in Patients with Congenital Factor XIII Deficiency </span></p>
<p>In 23 patients with congenital FXIII A-subunit deficiency on prophylaxis, the pharmacokinetics of rFXIII were evaluated over a dosing interval of 28 days during steady state.</p>
<p>The pharmacokinetic parameters based on steady state baseline adjusted FXIII activity (Berichrom assay) values are shown in Table 3.</p>
<p><span class="Bold">Table 3 	Pharmacokinetic parameters based on steady state baseline adjusted FXIII activity</span></p>
<table>
<col width="37%">
<col width="58%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Parameters</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Mean (SD)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">ss, max</span> (IU/mL)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.71 (0.17)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">ss</span>, <span class="Sub">min</span> (IU/mL)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.05 (0.05)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC<span class="Sub">(0-inf)</span> (IU*h/mL)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">128.3 (40.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clearance (mL/h/kg)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.33 (0.11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Half-life (days)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">5.1 (2.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">V<span class="Sub">ss </span>(mL/kg)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">65.9 (26.9)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">MRT (days)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">7.9 (3.4)</p></td>
</tr>
</tbody>
</table>
<p>At steady state, the pharmacokinetics of rFXIII are comparable with the single dose pharmacokinetics of rFXIII.</p>
<p><span class="Italics">Pediatric (Ages 1 to &lt; 6 Years Old)</span></p>
<p>In a pharmacokinetic trial six children with congenital FXIII A-subunit deficiency on prophylaxis treatment were administered a single intravenous dose of 35 IU/kg. The pharmacokinetic parameters based on baseline adjusted FXIII activity (Berichrom assay) values are shown in Table 4. No dose adjustment is needed for pediatric patients as there is no influence of age on the pharmacokinetics of TRETTEN.</p>
<p><span class="Bold">Table 4	 The pharmacokinetic parameters based on baseline adjusted FXIII activity</span></p>
<table>
<col width="33%">
<col width="59%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Parameters</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Mean (SD)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">max</span> (IU/mL)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.48 (0.14)   </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC<span class="Sub">(0-inf)</span> (IU*h/mL)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">107.8 ( 32.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clearance (mL/h/kg)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.41 (0.20)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Half-life (days)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">7.1 (1.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">V<span class="Sub">ss </span>(mL/kg)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">61.2 ( 41.0)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">MRT (days)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">7.5 (4.8)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_8814c4bc-c0b8-45d9-abe9-da30b0007fc7"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_971c38d9-8a80-4efd-8db2-7bef5b60988f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of TRETTEN, or studies to determine the effects of TRETTEN on genotoxicity or fertility have not been performed. An assessment of the carcinogenic potential of TRETTEN was completed and suggests minimal carcinogenic risk from product use.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_6526500e-6fde-4cdc-b595-fb9eaa6482d7"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Exaggerated pharmacologic effects, including general <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, ischemic <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and mortality were observed in nonclinical studies with TRETTEN and non-proteolytically activated recombinant FXIII at a dose of 1670 IU/kg, i.e., 48 times the recommended human dose of 35 IU/kg.</p>
<p>In a monkey cardiovascular safety pharmacology model evaluating the combination of excessive doses of TRETTEN (585 IU/kg, 17 times the expected human dose) in combination with rFVIIa (1000 mcg/kg, 11 times the expected human dose), one of the twelve monkeys died 4 hours after treatment due to <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. Procoagulant risk factors, including 6 indwelling catheters per monkey and the induction of anesthesia, may have complicated the study results. It is unclear whether the mortality was related to the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of one or both products, or a specific interaction between them. Nonclinical and clinical studies with the combination of TRETTEN and rFVIIa at recommended human doses have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_2102ef14-ff7f-454e-8932-01a699fa0123"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">To establish the efficacy of TRETTEN for the prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients with congenital FXIII A-subunit deficiency, a multi-center, open-label, non-controlled trial was conducted for 52 weeks in forty-one (41)<span class="Italics"> </span>subjects ≥ 6 years. All subjects received monthly doses of TRETTEN at 35<span class="Italics"> </span>IU/kg. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> episodes that required treatment with a FXIII-containing product were observed to evaluate the efficacy of monthly replacement therapy with TRETTEN on prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes. </p>
<p>Subjects with congenital FXIII A-subunit deficiency confirmed by genotyping were included. Subjects who before entering the trial had received regular replacement therapy were to have initiated regular replacement therapy at least 6 months prior to screening and were to have a documented history of at least one treatment-requiring <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode before initiation of regular replacement therapy or a documented family history of FXIII congenital deficiency. Subjects who before entering the trial had only received on-demand treatment were to have a documented history of at least two treatment-requiring <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes within 12 months of the screening visit. Severe bleeders as defined by a documented history of ≥2 treatment requiring <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleedings</span> per year during regular FXIII replacement therapy were excluded. </p>
<p>During the prophylaxis treatment period with TRETTEN (434<span class="Italics"> </span>subject months), five <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes treated with FXIII-containing products were observed in four subjects. All five were associated with <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. When calculated for all 41 subjects, this translated into a mean annual rate of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes that required  treatment of 0.14 [95% CI:0.058- 0.332] per subject year, which was statistically significantly lower than the historic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate of 1.68 per subject year for on-demand treatment. The age-adjusted rate of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes that required treatment during the TRETTEN treatment period was 0.05 [95% CI: 0.0094 - 0.2501] per subject year with a model-based estimate corresponding to the mean age of 26.4 years. The mean annual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate in patients below 18 years of age was higher compared to that in adults (0.362 versus 0.040 bleeds/subject/year). Table 5 below lists the estimated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rates by age.</p>
<p><span class="Bold">Table 5	Estimated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Rates by Age </span></p>
<table>
<col width="14%">
<col width="12%">
<col width="38%">
<col width="20%">
<col width="29%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Group</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Estimated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Rate (bleeds/subject/year)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">95% CI</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Historical Control Group Estimated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Rate</span></p>
<p><span class="Bold">(bleeds/subject/year)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">All</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">41</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.138</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">[0.058; 0.332]</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.68</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">&lt; 18 years</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.362</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">[0.136; 0.963]</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">2.00</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">≥ 18 years</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.040</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">[0.006; 0.283]</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.59</p></td>
</tr>
</tbody>
</table>
<p>Thirty-four (34) of the 41 subjects  and an additional 21 new subjects were enrolled in an ongoing second trial. During a total treatment period of 107.5 subject years (mean of 1.95 years per subject), 5 subjects experienced 6 bleeds that required treatment with a FXIII-containing product. The mean annual  rate of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes that required treatment was determined to be 0.056 per subject year. The age-adjusted rate of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes that required treatment during the TRETTEN treatment period was 0.022 per subject year [95% CI:0.0045; 0.1023] with a model-based estimate corresponding to a mean age of 29.5 years. The annual mean <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate in patients below age 18 was higher compared to that in adults (0.127 versus 0.026 bleeds/subject/year) with some overlap of the respective 95% confidence intervals. Table 6 lists the estimated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rates by age.</p>
<p><span class="Bold">Table 6 	Estimated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Rates by Age </span></p>
<table>
<col width="16%">
<col width="29%">
<col width="46%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Group</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Estimated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Rate</span></p>
<p><span class="Bold">(bleeds/subject/year)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">95% CI</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">All</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">          55</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.056</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">[0.025; 0.124]</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">&lt; 18 years</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.127</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">[0.048; 0.339]</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">≥ 18 years</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">39</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.026</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">[0.007; 0.105]</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_a71608b1-b5dd-472a-b57a-df1503f9bcd4"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Inbal, A., et.al<span class="Italics">.</span>:Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency, <span class="Italics">Blood</span>. 2012;119(22): 5111-5117</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_57a6a682-857e-4833-97f7-21172d93b573"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Italics">How Supplied</span></p>
<p>TRETTEN, Coagulation Factor XIII A-Subunit (Recombinant), is supplied as a white, lyophilized powder in single-use vial along with the diluent (Sterile Water for Injection) vial. </p>
<p>The actual amount of TRETTEN in international units (IU) is stated on each carton and vial. TRETTEN and the sterile water vials provided in the package are not made with natural rubber latex.</p>
<table>
<col width="31%">
<col width="27%">
<col width="42%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Presentation</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Carton NDC Number</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Components NDC Number</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">2000 - 3125 IU</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0169-7013-01</p></td>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>TRETTEN Single-use Vial   [NDC 0169-7113-11]</dd>
<dt>•</dt>
<dd>Sterile Water for Injection Vial [NDC 0169-7000-93]</dd>
</dl></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Storage and Handling</span></p>
<dl>
<dt>•</dt>
<dd>Store refrigerated at 2°C – 8°C (36°F – 46°F) prior to reconstitution. TRETTEN is stable until the expiration date on the carton and vial label. Do not freeze. Store protected from light.</dd>
<dt>•</dt>
<dd>Use reconstituted TRETTEN within 3 hours.  </dd>
<dt>•</dt>
<dd>If the reconstituted product is not used immediately, store the solution refrigerated or at room temperature not to exceed 25°C (77°F) for up to 3 hours following reconstitution.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_8392a0d2-1be2-4026-b10f-d954b9584657"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>Advise patients to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</dd>
<dt>•</dt>
<dd>Discuss the signs and symptoms of allergic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> experienced during or after injection of TRETTEN <span class="Italics">[<a href="#i4i_section_id_f0844e7a-bf79-48bf-b14f-add773e4bc99">see Warnings and Precautions (5.1)</a>].</span>
</dd>
<dt>•</dt>
<dd>Discuss signs and symptoms of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, such as limb or abdomen <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> or motor power, altered consciousness, vision, or speech <span class="Italics">[<a href="#i4i_section_id_8fae96f1-d8bd-4d8f-a499-b9e166a6ff66">see Warnings and Precautions (5.2)</a>].</span>
</dd>
<dt>•</dt>
<dd>Inform patients that breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be the sign and symptom of inhibitor formation <span class="Italics">[<a href="#i4i_section_id_4155c607-5f60-4535-b08b-1bb6d3c0550b">see Warnings and Precautions (5.3)</a>].</span>
</dd>
</dl>
<p class="First">License Number: 1261</p>
<p>TRETTEN<span class="Sup">®</span> is covered by US Patent No. 7,220,556 and other patents pending.</p>
<p><span class="Italics">Novo Nordisk<span class="Sup">®</span> is a registered trademark of Novo Nordisk A/S</span></p>
<p><span class="Italics">TRETTEN<span class="Sup">®</span> is a registered trademark of Novo Nordisk Health Care AG</span></p>
<p>© 2013-2014 Novo Nordisk</p>
<p>For Information contact:</p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, NJ 08536</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_29adf766-3ff0-4f7f-938b-18c17f7156a9"></a><a name="section-17"></a><p></p>
<h1>Patient Package Insert</h1>
<p class="First"><span class="Bold">TRETTEN<span class="Sup">®</span></span></p>
<p>Coagulation Factor XIII A-Subunit (Recombinant)</p>
<p>This leaflet summarizes important information about TRETTEN. Please read it carefully before using TRETTEN and each time you get a refill because there may be new information provided. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about TRETTEN. If you have any questions after reading this, ask your healthcare provider.</p>
<p><span class="Bold">What is TRETTEN?</span></p>
<p>TRETTEN is an injectable medicine used to prevent <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in adults and children who have congenital factor XIII (FXIII) A-subunit deficiency. TRETTEN is man-made and does not contain animal or human materials.</p>
<p><span class="Bold">Who should <span class="Underline">not</span> use TRETTEN?</span></p>
<p>You should <span class="Underline">not</span> use TRETTEN if you have ever had allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions, including severe, whole body reaction (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to TRETTEN or any of the ingredients.</p>
<p><span class="Bold">What should I tell my healthcare provider before TRETTEN is given? </span></p>
<p>Tell your healthcare provider about all of your medical conditions, including:</p>
<dl>
<dt>•</dt>
<dd>If you are pregnant, think you may be pregnant or planning to become pregnant. It is not known if TRETTEN can harm you or your unborn baby. </dd>
<dt>•</dt>
<dd>Labor and Delivery: It is not known if TRETTEN is safe and effective during labor and delivery.</dd>
<dt>•</dt>
<dd>Breast feeding: It is not known if TRETTEN passes into your breast milk.</dd>
<dt>•</dt>
<dd>If you have a history of blood clots.</dd>
</dl>
<p>Tell your healthcare provider about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.</p>
<p><span class="Bold">How is TRETTEN given?</span></p>
<p>TRETTEN is given as an injection into your vein (intravenous injection). These injections are given once a month. Your dose will depend on your body weight.  Use the dose that your healthcare provider has prescribed for you based on your weight. </p>
<p>Before injecting TRETTEN, it must be dissolved (reconstituted) using the sterile water that is provided in the package. Throw away any TRETTEN left in the vial after you inject your dose because it may become unsterile.</p>
<p><span class="Bold">What are the possible side effects of TRETTEN?</span></p>
<p>Call your healthcare provider or go to the emergency department right away if you have any of the following symptoms after using TRETTEN:</p>
<dl>
<dt>•</dt>
<dd>Signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> including<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> (<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the skin (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>Signs of a blood clot including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, warmth, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or a lump in your legs or arms, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and/or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or function </dd>
<dt>•</dt>
<dd>Unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></dd>
</dl>
<p>Other possible side effects may include:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your arms or legs</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the injection site</dd>
</dl>
<p>These are not all the possible side effects of TRETTEN. Tell your healthcare provider about any side effect that bothers you or that does not go away. You can also report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store TRETTEN?</span></p>
<p>It is important to store TRETTEN correctly. </p>
<dl>
<dt> </dt>
<dd><span class="Bold">Before preparing TRETTEN for injection</span></dd>
<dt> </dt>
<dd>Keep TRETTEN in a refrigerator at 36°F to 46°F (2°C to 8°C) and in the original package in order to protect it from light. Do not freeze TRETTEN.  </dd>
<dt> </dt>
<dd><span class="Bold">After preparing TRETTEN for injection (reconstituted)</span></dd>
</dl>
<p>	Use TRETTEN immediately after it is dissolved (reconstituted) using the sterile water provided in the package. </p>
<dl>
<dt> </dt>
<dd>If you cannot inject it immediately, either leave TRETTEN at room temperature not above 25°C (77°F) or put </dd>
<dt> </dt>
<dd>TRETTEN in the refrigerator at 36°F to 46°F (2°C to 8°C) for no more than 3 hours. After more than 3 hours, DO</dd>
<dt> </dt>
<dd>NOT USE IT—THROW IT AWAY.</dd>
<dt> </dt>
<dd>TRETTEN does not contain a preservative. Do not store TRETTEN in the syringe or placed in the freezer.</dd>
</dl>
<p><span class="Bold">What else should I know about TRETTEN?</span></p>
<p>Do not use TRETTEN for a condition for which it is not prescribed. Do not share TRETTEN with other people, even if they have the same symptoms that you have.</p>
<p>Talk to your healthcare provider if you would like more information.</p>
<p><span class="Bold">TRETTEN ingredients include:</span></p>
<dl>
<dt>•</dt>
<dd>Coagulation Factor XIII A-Subunit (Recombinant)</dd>
<dt>•</dt>
<dd>Sodium Chloride</dd>
<dt>•</dt>
<dd>Sucrose</dd>
<dt>•</dt>
<dd>Polysorbate 20</dd>
<dt>•</dt>
<dd>L-Histidine</dd>
</dl>
<p>TRETTEN and the sterile water vials provided in the package are not made with natural rubber latex.</p>
<p>This Patient Package Insert has been approved by the US Food and Drug Administration</p>
<p>Revised: 12/2013</p>
<p>Version: 1</p>
<p>Novo Nordisk<span class="Sup">®</span> is a registered trademark of Novo Nordisk A/S</p>
<p>TRETTEN<span class="Sup">®</span> is a registered trademark of Novo Nordisk Health Care AG</p>
<p>© 2013 Novo Nordisk</p>
<p>For Information contact:</p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, NJ 08536</p>
<p>www.novonordisk-us.com  </p>
<p>1-844-TRETTEN</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<table>
<col width="51%">
<col width="54%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First"><span class="Bold">Instructions for Use</span></p>
<p><span class="Bold">TRETTEN<span class="Sup">®</span></span></p>
<p><span class="Bold">Coagulation Factor XIII A-Subunit (Recombinant)</span></p>
<p><span class="Bold">(For intravenous use only)</span></p>
<p>READ THESE INSTRUCTIONS CAREFULLY BEFORE USING TRETTEN<span class="Sup">®</span>.</p>
<p><span class="Bold">Do not attempt to do an infusion yourself unless you have been taught by your healthcare provider or <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> center.</span></p>
<p>Always follow the specific instructions given by your healthcare provider. The steps listed below are general guidelines for using TRETTEN<span class="Sup">®</span>. If you are unsure of this procedure, please call your healthcare provider before using.</p>
<p>Always wash your hands and ensure that the area around you is clean.</p>
<p>When you prepare and inject medication directly into the veins, it is important to use a clean and germ free (aseptic) technique. Improper technique can introduce germs that can infect the blood.</p>
<p>Your healthcare provider will prescribe the dose that you should take.</p>
<p>TRETTEN<span class="Sup">®</span> is supplied as a powder. Before injection (administration) it must be mixed (reconstituted) with the sterile water supplied in a separate vial. The mixed TRETTEN<span class="Sup">®</span> must be injected into your vein (intravenous injection).  </p>
<p>For reconstitution of the TRETTEN<span class="Sup">®</span> you will need a syringe and sterile alcohol swabs (not included in the package).</p>
<p><span class="Bold">Do not open the package until you are ready to use it.</span></p>
<p><span class="Bold">Do not use TRETTEN</span><span class="Sup">®</span><span class="Bold"> if it is expired. </span>Use a new package instead. The expiration date is printed on the outer carton and on the vials. </p>
<p><span class="Bold">Do not use TRETTEN</span><span class="Sup">®</span><span class="Bold"> if the contents in the package appear damaged.</span> Use a new package instead.</p>
<p><span class="Bold">TRETTEN</span><span class="Sup">®</span><span class="Bold"> is for single use only.</span></p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">Content</span></p>
<p>The package contains:</p>
<p>• Vial with TRETTEN<span class="Sup">®</span> powder</p>
<p>• Vial with sterile water (diluent) </p>
<p>• Vial adapter</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">
<a name="id-758603142"></a><img alt="Tretten Vials" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-11.jpg"><a name="id2042542160"></a><img alt="Vial Adapter" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-12.jpg">
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Reconstitute TRETTEN</span><span class="Sup">®</span><span class="Bold"> using the following procedure</span></p>
<dl>
<dt>•</dt>
<dd>Take out the number of TRETTEN<span class="Sup">®</span> packages you need. </dd>
<dt>•</dt>
<dd>Check the expiry date. </dd>
<dt>•</dt>
<dd>Check the name on the package, to make sure it contains the correct product.</dd>
<dt>•</dt>
<dd>Wash your hands and dry them properly using a clean towel or air dry. </dd>
<dt>•</dt>
<dd>Bring TRETTEN<span class="Sup">®</span> (white lyophilized powder) and sterile water (diluent) to room temperature, but not above 25°C (77°F).</dd>
<dt>•</dt>
<dd>Remove the plastic caps from the two vials. If the plastic cap is loose or missing, do not use the vial.</dd>
<dt>•</dt>
<dd>Wipe the rubber stopper with a sterile alcohol swab and allow it to air dry for a few seconds before use to ensure that it is as germ free as possible.</dd>
<dt>•</dt>
<dd>Do not touch the rubber stopper with your fingers as this can transfer germs.</dd>
<dt>•</dt>
<dd>Hold the vial adapter using the protective cap. Remove the protective paper but do not take the vial adapter out of the protective cap. Do not touch the spike on the vial adapter. If the protective paper is not fully sealed or if it is broken, do not use the vial adapter.</dd>
<dt>•</dt>
<dd>Place the diluent vial on a flat and solid surface. </dd>
<dt>•</dt>
<dd>Attach the vial adapter to the diluent vial, without taking the vial adapter out of the protective cap as shown in Figure A. </dd>
<dt>•</dt>
<dd>Once attached, remove the protective cap from the vial adapter by lightly squeezing the protective cap with your thumb and index finger as shown in Figure B.</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id1041555811"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-13.jpg"><a name="id-186602888"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-14.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Pull back the plunger of the sterile syringe to draw in a volume of 3.2 mL air into the syringe as shown in Figure C.</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id504105924"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-15.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Screw the syringe tightly on to the vial adapter on the diluent vial as shown in Figure D.</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id-1551915763"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-16.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Inject the air from the syringe into the diluent vial until resistance is felt. Then hold the syringe with the diluent vial upside down and withdraw 3.2 mL of sterile water into the syringe as shown in Figure E.</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id1191878102"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-17.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Remove the empty diluent vial from the vial adapter by tipping the syringe and vial adapter as shown in Figure F.</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id-1960094660"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-18.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Attach the syringe with the vial adapter to the powder vial. Hold the syringe slightly tilted with the vial facing downwards. </dd>
<dt>•</dt>
<dd>Push the plunger slowly to inject all sterile water (3.2 mL) into the powder vial as shown in Figure G. </dd>
<dt>•</dt>
<dd>Do not inject the sterile water directly on the TRETTEN<span class="Sup">®</span> powder to avoid foaming.</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id-667791168"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-19.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Gently swirl the vial until all the powder is dissolved as shown in Figure H. Do not shake the vial. </dd>
<dt>•</dt>
<dd>The reconstituted TRETTEN<span class="Sup">®</span> should be a clear and colorless solution. </dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id877747833"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-20.jpg">
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First"><span class="Bold">Reconstituted TRETTEN</span><span class="Sup">®</span><span class="Bold"> should be used immediately</span>. If not used immediately store refrigerated or at room temperature not to exceed 25°C (77°F) for up to 3 hours. Discard after 3 hours.</p>
<p><span class="Bold">Do not freeze mixed TRETTEN</span><span class="Sup">®</span><span class="Bold"> solution or store it in syringes.</span></p>
<p><span class="Bold">Keep mixed TRETTEN</span><span class="Sup">®</span><span class="Bold"> solution out of direct light.</span></p>
<p>To administer a larger dose, reconstitute each additional vial as required using the same procedure with a separate syringe.</p>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Inject the mixed solution</span></p>
<dl>
<dt>•</dt>
<dd>Keep the plunger pushed all the way in before turning the syringe upside down. </dd>
<dt>•</dt>
<dd>Pull the plunger slightly downwards to draw the mixed solution into the syringe as shown in Figure I. </dd>
<dt>•</dt>
<dd>Only withdraw the amount of mixed solution that your doctor has prescribed, using the scale on the syringe.</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id-1756589253"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-21.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><dl>
<dt>•</dt>
<dd>Unscrew the syringe from the vial adapter and vial as shown in Figure J.</dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id-1569641082"></a><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-22.jpg">
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">TRETTEN<span class="Sup">®</span> is now ready to inject as instructed by your healthcare provider.</p>
<dl>
<dt>•</dt>
<dd>Remember to only use the amount of TRETTEN<span class="Sup">®</span> prescribed by your healthcare provider.</dd>
<dt>•</dt>
<dd>Do not infuse any faster than 1-2 mL per minute.</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Disposal</span></p>
<dl>
<dt>•</dt>
<dd>After injection, safely dispose of the syringe, the vial with the vial adapter, any unused TRETTEN<span class="Sup">®</span> and other waste materials as instructed by your healthcare provider.</dd>
</dl>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<a name="id-1069412368"></a><img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-23.jpg">
</td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="2" valign="top">
<p class="First">For Full Prescribing Information please read the other insert included in this package.</p>
<p>Revised: 12/2013</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>2880 Bagsvaerd, Denmark</p>
<p>License Number: 1261</p>
<p>Version: 20131223-v1</p>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a837b75b-5018-4b60-911b-44b89e74735e"></a><a name="section-18"></a><p></p>
<h1>PACKAGE/LABEL DISPLAY PANEL</h1>
<p class="First">NDC 0169-7013-01	LIST: 701301</p>
<p><span class="Bold">2500 IU</span></p>
<p><span class="Bold">TRETTEN<span class="Sup">®</span></span></p>
<p>Coagulation Factor XIII A-Subunit (Recombinant)</p>
<p>For intravenous administration only</p>
<p>For human use only</p>
<p>Contains no preservative</p>
<p>Rx only</p>
<div class="Figure">
<a name="id-1403064675"></a><img alt="Tretten Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-24.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c6a64d35-459f-4e62-98aa-a91e57ff1876"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">NDC 0169-7113-11	LIST: 711311</p>
<p><span class="Bold">2500 IU</span></p>
<p><span class="Bold">TRETTEN<span class="Sup">®</span></span></p>
<p>Coagulation Factor XIII A-Subunit (Recombinant)</p>
<p>For intravenous administration only</p>
<p><span class="Bold">Store refrigerated at 2-8°C (36-46°F)</span></p>
<p>Reconstitute with 3.2 mL sterile water for injection only</p>
<p>Rx only</p>
<p>Novo Nordisk Inc.</p>
<p>1-844-TRETTEN</p>
<p>Expiry/Lot/rFXIII IU per vial:</p>
<div class="Figure">
<a name="id618811183"></a><img alt="Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-25.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_bc08bc37-4f1f-443a-b0e8-b12bbed3ea00"></a><a name="section-20"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">NDC 0169-7000-93	LIST: 700093</p>
<p><span class="Bold">3.2 mL</span></p>
<p><span class="Bold">Sterile Water for Injection</span></p>
<p>For reconstitution of TRETTEN<span class="Sup">®</span></p>
<p>Coagulation Factor XIII A-Subunit (Recombinant)</p>
<p><span class="Bold">Store at 2-25°C (36-77°F)</span></p>
<p>Novo Nordisk Inc.</p>
<p>1-844-TRETTEN</p>
<p>Expiry/Lot/:</p>
<div class="Figure">
<a name="id276384035"></a><img alt="Sterile water for injection" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8664978e-1814-4930-aca5-97a24455f6df&amp;name=f4607f56-9618-4a12-a047-c0de02cafe05-26.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRETTEN 		
					</strong><br><span class="contentTableReg">coagulation factor xiii a-subunit (recombinant) kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0169-7013</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0169-7013-01</td>
<td class="formItem">1  in 1 KIT</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">0 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">0 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>TRETTEN 		
					</strong><br><span class="contentTableReg">coagulation factor xiii a-subunit (recombinant) injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0169-7113</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FACTOR XIII CONCENTRATE (HUMAN)</strong> (FACTOR XIII CONCENTRATE (HUMAN)) </td>
<td class="formItem">FACTOR XIII CONCENTRATE (HUMAN)</td>
<td class="formItem">2500 [iU]  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">8.7 mg  in 3 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">174 mg  in 3 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem">0.30 mg  in 3 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem">9.30 mg  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0169-7113-11</td>
<td class="formItem">3 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125398</td>
<td class="formItem">12/23/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">sterile water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0169-7000</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">3.2 mL  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0169-7000-93</td>
<td class="formItem">3.2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125398</td>
<td class="formItem">12/23/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125398</td>
<td class="formItem">12/23/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novo Nordisk
							(622920320)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novo Nordisk A/S</td>
<td class="formItem"></td>
<td class="formItem">306711800</td>
<td class="formItem">MANUFACTURE(0169-7013)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f4607f56-9618-4a12-a047-c0de02cafe05</div>
<div>Set id: 8664978e-1814-4930-aca5-97a24455f6df</div>
<div>Version: 2</div>
<div>Effective Time: 20140430</div>
</div>
</div> <div class="DistributorName">Novo Nordisk</div></p>
</body></html>
